EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

Hengyi Chen, Hongling Yang, Lu Guo, Qingxiang Sun iD

MedComm · 2025-10 · 6 (10)

DOI: 10.1002/mco2.70412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 05.10.2025. Verfasst von Hengyi Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine The Seventh People's Hospital of Chongqing Chongqing China. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid development of immune checkpoint inhibitors has fundamentally changed the landscape of cancer treatment. These agents restore T cell‐mediated antitumor immune responses by targeting key immune checkpoint molecules, thereby suppressing or eliminating tumors. However, their clinical application still faces multiple challenges, mainly including efficacy heterogeneity, drug resistance, immune‐related adverse events. Furthermore, there is still a lack of reliable biomarkers for predicting efficacy and toxicity. More critically, there is absence of precise predictive models that can systematically integrate multiomics features, dynamic tumor microenvironment evolution, and patient individual differences to comprehensively address the above issues. This review systematically summarizes the latest advancements in this field. The main contents include emerging targets like lymphocyte activation gene 3, T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif domain, and mucin‐domain‐containing‐3, combination strategies, and the current research status and limitations of various predictive biomarkers. Moreover, it focuses on the potential of microbiome regulation, metabolic reprogramming, and artificial intelligence‐driven multiomics analysis technologies in achieving dynamic patient stratification and personalized treatment. By integrating the frontier research results and clinical insights, the review aims to provide a systematical theory framework and future directions for advancing precision immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

CTLA‐4PD‐1/PD‐L1combination therapydrug resistanceimmune checkpoint inhibitorsprecision immunotherapytumor microenvironment

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine The Seventh People's Hospital of Chongqing Chongqing China.
  • Department of Nephrology and Institute of Nephrology Sichuan Provincial People's Hospital School of Medicine Sichuan Clinical Research Centre for Kidney Diseases University of Electronic Science and Technology of China…
  • Department of Pulmonary and Critical Care Medicine Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China Chengdu China.

ORCID-Profile: Qingxiang Sun

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Chen, H., Yang, H., Guo, L., & Sun, Q. (2025). The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances. MedComm, 6(10). https://doi.org/10.1002/mco2.70412

Vancouver

Chen H, Yang H, Guo L, Sun Q. The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances. MedComm. 2025;6(10). doi:10.1002/mco2.70412

BibTeX
@article{Chen2025,
  author = {Chen, Hengyi and Yang, Hongling and Guo, Lu and Sun, Qingxiang},
  title = {The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {10},
  doi = {10.1002/mco2.70412}
}
Kostenlos starten →